Among them, specific caspase-1 inhibitors could be evaluated, including VX-765 (belnacasan) for which phase II clinical trials for the treatment of psoriasis have been completed, and VX-740 (pralnacasan) for which phase II clinical trials are in progress for the treatment of rheumatoid arthritis and osteoarthritis (Dhani et al., 2021). This evidence concerns the gene CASP1 and osteoarthritis.